BCEL vs. IMNN, EDSA, RDHL, MIRA, KPRX, AVTX, HUGE, PIRS, ELAB, and KTRA
Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include Imunon (IMNN), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), MIRA Pharmaceuticals (MIRA), Kiora Pharmaceuticals (KPRX), Avalo Therapeutics (AVTX), FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), Elevai Labs (ELAB), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
Atreca (NASDAQ:BCEL) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
In the previous week, Imunon had 1 more articles in the media than Atreca. MarketBeat recorded 1 mentions for Imunon and 0 mentions for Atreca. Imunon's average media sentiment score of 1.87 beat Atreca's score of 0.00 indicating that Imunon is being referred to more favorably in the news media.
Atreca has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500.
Imunon's return on equity of -122.68% beat Atreca's return on equity.
Imunon has higher revenue and earnings than Atreca. Imunon is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
37.5% of Atreca shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 11.3% of Atreca shares are owned by insiders. Comparatively, 5.0% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Imunon has a consensus price target of $12.00, indicating a potential upside of 733.33%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Atreca.
Atreca received 86 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 67.86% of users gave Atreca an outperform vote.
Summary
Imunon beats Atreca on 11 of the 16 factors compared between the two stocks.
Get Atreca News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
